Abstracts tagged "randomized trials and systemic vasculitides"

Abstract Number: 1086 • 2015 ACR/ARHP Annual Meeting
Does Adding Azathioprine to Glucocorticoid Induction Increase the Remission Rate and Prevent Relapses in Patients with Systemic Necrotizing Vasculitides without Poor-Prognosis Factors? a Multicenter, Double-Blind Randomized Controlled Trial
Xavier Puéchal¹, Christian Pagnoux², Gabriel Baron³, Thomas Quémeneur⁴, Antoine Néel⁵, Christian Agard⁵, François Lifermann⁶, Eric Liozon⁷, Marc Ruivard⁸, Pascal Godmer⁹, Nicolas Limal¹⁰, Arsène Mékinian¹¹, Thomas Papo¹², Anne-Marie Ruppert¹³, Anne Bourgarit-Durand¹⁴, Boris Bienvenu¹⁵, Loïck Geffray¹⁶, Jean-Luc Saraux¹⁷, Elisabeth Diot¹⁸, Bruno Crestani¹², Xavier Delbrel¹⁹, Laurent Sailler²⁰, Pascal Cohen¹, Véronique Le Guern²¹, Benjamin Terrier¹, Matthieu Groh²¹, Claire Le Jeunne²¹, Luc Mouthon²¹, Philippe Ravaud³ and Loïc Guillevin for The French Vasculitis Study Group²¹, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Hôpital Hôtel Dieu, Paris, France, ⁴CH Valenciennes, Valenciennes, France, ⁵CHU Nantes, Nantes, France, ⁶CH Dax, Dax, France, ⁷CHU Limoges, Limoges, France, ⁸CHU Clermont-Ferrand, Clermont–Ferrand, France, ⁹CH Vannes, Vannes, France, ¹⁰CHU Créteil, Créteil, France, ¹¹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ¹²CHU Bichat, Paris, France, ¹³CHU Tenon, Paris, France, ¹⁴CHU Bondy, Bondy, France, ¹⁵Internal Medicine, Hospital Caen, Caen, France, ¹⁶CH Lisieux, Lisieux, France, ¹⁷CH Eaubonne, Eaubonne, France, ¹⁸CHU Tours, Tours, France, ¹⁹CH Pau, Pau, France, ²⁰CHU Toulouse, Toulouse, France, ²¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Glucocorticoids (GC) achieve remission in most patients with systemic necrotizing vasculitides (SNVs) without poor-prognosis factors based on the 1996 Five-Factor Score (FFS; comprising creatininemia…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].